Literature DB >> 16775498

Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.

Michael R Konikoff1, Lee A Denson.   

Abstract

Calprotectin is an abundant neutrophil protein found in both plasma and stool that is markedly elevated in infectious and inflammatory conditions, including inflammatory bowel disease (IBD). We conducted a systematic review of the published literature regarding fecal calprotectin to evaluate its potential as a noninvasive marker of neutrophilic intestinal inflammation. Reference ranges for fecal calprotectin have been established in healthy adults and children, and elevated concentrations of fecal calprotectin have been demonstrated in numerous studies of patients with IBD. Fecal calprotectin correlates well with histological inflammation as detected by colonoscopy with biopsies and has been shown successfully to predict relapses and detect pouchitis in patients with IBD. Fecal calprotectin has been shown to consistently differentiate IBD from irritable bowel syndrome because it has excellent negative predictive value in ruling out IBD in undiagnosed, symptomatic patients. Fecal calprotectin also may be useful in determining whether clinical symptoms in patients with known IBD are caused by disease flares or noninflammatory complications/underlying irritable bowel syndrome and in providing objective evidence of response to treatment. Although more studies are needed to define fully the role of fecal calprotectin, convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775498     DOI: 10.1097/00054725-200606000-00013

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  121 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  T Kaiser; J Langhorst; H Wittkowski; K Becker; A W Friedrich; A Rueffer; G J Dobos; J Roth; D Foell
Journal:  Gut       Date:  2007-08-03       Impact factor: 23.059

4.  Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity.

Authors:  William E Ruff; Carina Dehner; Woo J Kim; Odelya Pagovich; Cassyanne L Aguiar; Andrew T Yu; Alexander S Roth; Silvio Manfredo Vieira; Christina Kriegel; Olamide Adeniyi; Melissa J Mulla; Vikki M Abrahams; William W Kwok; Ruth Nussinov; Doruk Erkan; Andrew L Goodman; Martin A Kriegel
Journal:  Cell Host Microbe       Date:  2019-06-18       Impact factor: 21.023

5.  Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

Authors:  David Berman; Susan M Parker; Jonathan Siegel; Scott D Chasalow; Jeffrey Weber; Susan Galbraith; Stephan R Targan; Hanlin L Wang
Journal:  Cancer Immun       Date:  2010-11-24

6.  Can we use faecal calprotectin to distinguish abdominal pain of familial Mediterranean fever (FMF) from acute appendicitis?

Authors:  Balahan Makay; Ozer Makay; Erbil Unsal
Journal:  Clin Rheumatol       Date:  2008-11-25       Impact factor: 2.980

7.  Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.

Authors:  O Grip; S Janciauskiene; A Bredberg
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

8.  Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis.

Authors:  Nobin Babu Kalappurayil; Jino Thomas; Baburajan Mankuni; Varghese Thomas
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 9.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

10.  Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.

Authors:  Jernej Dolinšek; Petra Rižnik; Larisa Sabath; Dušanka Mičetić-Turk
Journal:  Wien Klin Wochenschr       Date:  2015-12-10       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.